

Jean-SÃ©bastien Hulot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/221596/publications.pdf>

Version: 2024-02-01

238
papers

20,769
citations

13865

67
h-index

10734

138
g-index

258
all docs

258
docs citations

258
times ranked

23978
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003.	2.2	3,915
2	Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1821.	7.4	980
3	Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. <i>Lancet</i> , The, 2009, 373, 309-317.	13.7	864
4	Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. <i>Blood</i> , 2006, 108, 2244-2247.	1.4	854
5	Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 317-323.	4.7	795
6	Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial. <i>Circulation</i> , 2001, 103, 1428-1433.	1.6	461
7	Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 328-332.	4.7	422
8	Natural History and Risk Stratification of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. <i>Circulation</i> , 2004, 110, 1879-1884.	1.6	387
9	Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration. <i>Journal of the American College of Cardiology</i> , 2010, 56, 134-143.	2.8	348
10	Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. <i>Lancet</i> , The, 2010, 376, 1476-1484.	13.7	330
11	Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. <i>Nature</i> , 2020, 581, 310-315.	27.8	283
12	Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 54, 3284-3290.	6.7	274
13	Feasibility and safety of ultrasound-aided thoracentesis in mechanically ventilated patients. <i>Intensive Care Medicine</i> , 1999, 25, 955-958.	8.2	270
14	Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020, 22, 1504-1524.	7.1	234
15	Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 295-304.	10.7	232
16	Association between ABCC2 Gene Haplotypes and Tenofovir-Induced Proximal Tubulopathy. <i>Journal of Infectious Diseases</i> , 2006, 194, 1481-1491.	4.0	230
17	A PDGFR α -Mediated Switch toward CD9high Adipocyte Progenitors Controls Obesity-Induced Adipose Tissue Fibrosis. <i>Cell Metabolism</i> , 2017, 25, 673-685.	16.2	195
18	The continuous heart failure spectrum: moving beyond an ejection fraction classification. <i>European Heart Journal</i> , 2019, 40, 2155-2163.	2.2	195

#	ARTICLE	IF	CITATIONS
19	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the <scp>Cardioâ€œOncology Study Group</scp> of the <scp>Heart Failure Association</scp> and the <scp>Cardioâ€œOncology Council of the European Society of Cardiology</scp>. <i>European Journal of Heart Failure</i> , 2020, 22, 1966-1983.	7.1	184
20	Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naïve HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 743-746.	0.7	182
21	Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1765-74.	7.4	179
22	Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 821-824.	0.9	176
23	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Associationâ€œEuropean Society of Cardiology. <i>European Heart Journal</i> , 2018, 39, 4243-4254.	2.2	171
24	Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. <i>European Heart Journal</i> , 2007, 28, 457-462.	2.2	168
25	Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1786-1792.	0.9	160
26	Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. <i>Nature Communications</i> , 2015, 6, 6955.	12.8	155
27	Renal safety of tenofovir in HIV treatment-experienced patients. <i>Aids</i> , 2004, 18, 1074-1076.	2.2	153
28	Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium. <i>FASEB Journal</i> , 2014, 28, 644-654.	0.5	148
29	Genetic Variants of the Î±-Synuclein Gene SNCA Are Associated with Multiple System Atrophy. <i>PLoS ONE</i> , 2009, 4, e7114.	2.5	144
30	Critical Role for Stromal Interaction Molecule 1 in Cardiac Hypertrophy. <i>Circulation</i> , 2011, 124, 796-805.	1.6	144
31	The CLIPMERGE PGx Program: Clinical Implementation of Personalized Medicine Through Electronic Health Records and Genomicsâ€œPharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 214-217.	4.7	144
32	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 159-165.	1.5	141
33	Small Molecule-Mediated Directed Differentiation of Human Embryonic Stem Cells Toward Ventricular Cardiomyocytes. <i>Stem Cells Translational Medicine</i> , 2014, 3, 18-31.	3.3	141
34	Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies. <i>Kidney International</i> , 2004, 66, 1153-1158.	5.2	138
35	Differential Effects of Lipid-Lowering Therapies on Stroke Prevention. <i>Archives of Internal Medicine</i> , 2003, 163, 669.	3.8	137
36	High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. <i>European Heart Journal</i> , 2012, 33, 1241-1249.	2.2	127

#	ARTICLE	IF	CITATIONS
37	A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 277-285.	1.5	125
38	Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. <i>Rheumatology</i> , 2007, 46, 808-810.	1.9	124
39	High Doses of Clopidogrel to Overcome Genetic Resistance. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 392-402.	2.9	118
40	Determinants of Hydroxychloroquine Blood Concentration Variations in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2015, 67, 2176-2184.	5.6	118
41	Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2153-2155.	3.8	117
42	Can We Override Clopidogrel Resistance?. <i>Circulation</i> , 2009, 119, 2854-2857.	1.6	115
43	The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1409-1411.	3.8	114
44	CYP2C19 But Not PON1 Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post-Myocardial Infarction Patients. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 422-428.	3.9	110
45	Gene therapy for the treatment of heart failure: promise postponed. <i>European Heart Journal</i> , 2016, 37, 1651-1658.	2.2	110
46	Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation. <i>Journal of Clinical Investigation</i> , 2008, 118, 2747-2757.	8.2	105
47	Cardiomyopathy Related to Antimalarial Therapy with Illustrative Case Report. <i>Cardiology</i> , 2007, 107, 73-80.	1.4	103
48	Renal Tubular Drug Transporters. <i>Nephron Physiology</i> , 2006, 103, p97-p106.	1.2	102
49	Plasticity of Surface Structures and β_2 -Adrenergic Receptor Localization in Failing Ventricular Cardiomyocytes During Recovery From Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 357-365.	3.9	102
50	Combinatorial, additive and dose-dependent drug-microbiome associations. <i>Nature</i> , 2021, 600, 500-505.	27.8	102
51	Changes in Enoxaparin Pharmacokinetics During Pregnancy and Implications for Antithrombotic Therapeutic Strategy. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 370-377.	4.7	98
52	Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. <i>European Heart Journal</i> , 2004, 25, 1788-1796.	2.2	97
53	Therapeutic Efficacy of AAV1.SERCA2a in Monocrotaline-Induced Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 128, 512-523.	1.6	97
54	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020, 22, 2272-2289.	7.1	92

#	ARTICLE	IF	CITATIONS
55	ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure. <i>Cardiovascular Research</i> , 2019, 115, 488-500.	3.8	90
56	Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. <i>Pharmacogenomics Journal</i> , 2013, 13, 369-377.	2.0	87
57	Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. <i>Arthritis and Rheumatism</i> , 2010, 62, 2047-2054.	6.7	85
58	Cardiac <i>Stim1</i> Silencing Impairs Adaptive Hypertrophy and Promotes Heart Failure Through Inactivation of mTORC2/Akt Signaling. <i>Circulation</i> , 2016, 133, 1458-1471.	1.6	84
59	Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 2888-2897.	8.2	83
60	RNA Interference Targeting STIM1 Suppresses Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat. <i>Molecular Therapy</i> , 2009, 17, 455-462.	8.2	82
61	The <i>COMT</i> Val158Met polymorphism affects the response to entacapone in Parkinson's disease: A randomized crossover clinical trial. <i>Annals of Neurology</i> , 2011, 69, 111-118.	5.3	82
62	Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells. <i>ELife</i> , 2017, 6, .	6.0	82
63	Long-Term Evolution of Premature Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1868-1878.	2.8	81
64	Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes. <i>Circulation Research</i> , 2014, 114, 1929-1943.	4.5	79
65	Role of sarco/endoplasmic reticulum calcium content and calcium ATPase activity in the control of cell growth and proliferation. <i>Pflugers Archiv European Journal of Physiology</i> , 2009, 457, 673-685.	2.8	78
66	Obesity Doubles Mortality in Patients Hospitalized for Severe Acute Respiratory Syndrome Coronavirus 2 in Paris Hospitals, France: A Cohort Study on 5,795 Patients. <i>Obesity</i> , 2020, 28, 2282-2289.	3.0	76
67	Effect of intracoronary administration of <i>AAV1</i> / <i>SERCA2a</i> on ventricular remodelling in patients with advanced systolic heart failure: results from the <i>AGENTâ€‘HF</i> randomized phase 2 trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1534-1541.	7.1	75
68	Cytotoxic CD8+ T cells promote granzyme B-dependent adverse post-ischemic cardiac remodeling. <i>Nature Communications</i> , 2021, 12, 1483.	12.8	73
69	Cyclic Nucleotide Compartmentalization: Contributions of Phosphodiesterases and ATP-Binding Cassette Transporters. <i>Annual Review of Pharmacology and Toxicology</i> , 2013, 53, 231-253.	9.4	71
70	Cardiac myocyteâ€‘secreted cAMP exerts paracrine action via adenosine receptor activation. <i>Journal of Clinical Investigation</i> , 2014, 124, 5385-5397.	8.2	70
71	Androgenic Effects on Ventricular Repolarization. <i>Circulation</i> , 2019, 140, 1070-1080.	1.6	67
72	Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 542-552.	4.7	66

#	ARTICLE	IF	CITATIONS
73	Curative anticoagulation prevents endothelial lesion in COVID-19 patients. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2391-2399.	3.8	66
74	Stem Cell Factor Gene Transfer Promotes Cardiac Repair After Myocardial Infarction via In Situ Recruitment and Expansion of c-kit ⁺ Cells. <i>Circulation Research</i> , 2012, 111, 1434-1445.	4.5	63
75	Considerations for pre-clinical models and clinical trials of pluripotent stem cell-derived cardiomyocytes. <i>Stem Cell Research and Therapy</i> , 2014, 5, 1.	5.5	62
76	Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes. <i>FASEB Journal</i> , 2012, 26, 1009-1017.	0.5	61
77	Genomic correction of familial cardiomyopathy in human engineered cardiac tissues. <i>European Heart Journal</i> , 2016, 37, 3282-3284.	2.2	60
78	Downregulation of the calcium current in human right atrial myocytes from patients in sinus rhythm but with a high risk of atrial fibrillation. <i>European Heart Journal</i> , 2008, 29, 1190-1197.	2.2	58
79	Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. <i>Fundamental and Clinical Pharmacology</i> , 2004, 18, 113-123.	1.9	57
80	Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 409-416.	1.9	54
81	Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up. <i>Lupus Science and Medicine</i> , 2014, 1, e000027.	2.7	54
82	Towards Precision Medicine With Human iPSCs for Cardiac Channelopathies. <i>Circulation Research</i> , 2019, 125, 653-658.	4.5	53
83	Influence of endogenous oestrogens on QT interval duration. <i>European Heart Journal</i> , 2003, 24, 1663-1667.	2.2	52
84	Effect of Renal Function on the Pharmacokinetics of Enoxaparin and Consequences on Dose Adjustment. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 305-310.	2.0	52
85	Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice. <i>Blood</i> , 2015, 126, 1823-1830.	1.4	51
86	Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. <i>American Heart Journal</i> , 2003, 146, 729-735.	2.7	48
87	Pharmacokinetic Study of Mycophenolate Mofetil in Patients with Systemic Lupus Erythematosus and Design of Bayesian Estimator Using Limited Sampling Strategies. <i>Clinical Pharmacokinetics</i> , 2008, 47, 277-284.	3.5	48
88	Effectiveness of gene delivery systems for pluripotent and differentiated cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 14067.	4.1	47
89	Emerging Drug Classes and Their Potential Use in Hypertension. <i>Hypertension</i> , 2019, 74, 1075-1083.	2.7	46
90	MRP4 (ABCC4) as a potential pharmacologic target for cardiovascular disease. <i>Pharmacological Research</i> , 2016, 107, 381-389.	7.1	45

#	ARTICLE	IF	CITATIONS
91	Functional Human Beige Adipocytes From Induced Pluripotent Stem Cells. <i>Diabetes</i> , 2017, 66, 1470-1478.	0.6	42
92	Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 626-633.	2.3	41
93	Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. <i>Pharmacogenomics Journal</i> , 2013, 13, 507-513.	2.0	40
94	CRISPR/Cas9 gene-editing strategies in cardiovascular cells. <i>Cardiovascular Research</i> , 2020, 116, 894-907.	3.8	40
95	Cardiac performance in patients hospitalized with COVID-19: a 6-month follow-up study. <i>ESC Heart Failure</i> , 2021, 8, 2232-2239.	3.1	40
96	Epistatic Gene-Based Interaction Analyses for Glaucoma in eMERGE and NEIGHBOR Consortium. <i>PLoS Genetics</i> , 2016, 12, e1006186.	3.5	38
97	Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19 genotyped healthy subjects. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 610-613.	3.8	36
98	Emergence of Orai3 activity during cardiac hypertrophy. <i>Cardiovascular Research</i> , 2015, 105, 248-259.	3.8	36
99	Antiplatelet drug interactions with proton pump inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 175-189.	3.3	35
100	Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, e1337-e1344.	5.8	35
101	Resident PW1 ⁺ Progenitor Cells Participate in Vascular Remodeling During Pulmonary Arterial Hypertension. <i>Circulation Research</i> , 2016, 118, 822-833.	4.5	34
102	The lipodystrophic hotspot lamin A p.R482W mutation deregulates the mesodermal inducer T/Brachyury and early vascular differentiation gene networks. <i>Human Molecular Genetics</i> , 2018, 27, 1447-1459.	2.9	34
103	Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. <i>Lancet Rheumatology</i> , The, 2022, 4, e24-e32.	3.9	34
104	Potent human broadly SARS-CoV-2 neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	34
105	Pharmacology and mechanisms of action of new oral anticoagulants. <i>Fundamental and Clinical Pharmacology</i> , 2015, 29, 10-20.	1.9	33
106	Assessment of signal quality measured with a smart 12-lead ECG acquisition T-shirt. <i>Annals of Noninvasive Electrocardiology</i> , 2020, 25, e12682.	1.1	33
107	Endothelial Cell Indoleamine 2, 3-Dioxygenase 1 Alters Cardiac Function After Myocardial Infarction Through Kynurenine. <i>Circulation</i> , 2021, 143, 566-580.	1.6	33
108	Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 100, 230-235.	2.8	32

#	ARTICLE	IF	CITATIONS
109	miR-322 regulates insulin signaling pathway and protects against metabolic syndrome-induced cardiac dysfunction in mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 611-621.	3.8	32
110	PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 374-383.	2.1	32
111	Dietary Assessment in the MetaCardis Study: Development and Relative Validity of an Online Food Frequency Questionnaire. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2017, 117, 878-888.	0.8	32
112	COVID-19 in patients with cardiovascular diseases. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 225-226.	1.6	32
113	Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e40-e48.	3.9	32
114	Beta-blocker treatment in heart failure. <i>Fundamental and Clinical Pharmacology</i> , 2001, 15, 95-109.	1.9	31
115	Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 364-373.	2.4	31
116	Hydroxychloroquine in systemic lupus erythematosus. <i>Lancet</i> , The, 2007, 369, 1257-1258.	13.7	31
117	Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1315-1324.	1.9	31
118	Association Between Psychological Distress, Cognitive Complaints, and Neuropsychological Status After a Severe COVID-19 Episode: A Cross-Sectional Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 725861.	2.6	31
119	Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: A combined analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 65, 212-221.	1.7	30
120	Association of Oral Contraceptives With Drug-Induced QT Interval Prolongation in Healthy Nonmenopausal Women. <i>JAMA Cardiology</i> , 2018, 3, 877.	6.1	30
121	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2022, 118, 3016-3051.	3.8	30
122	Proteinuria and Clinical Outcomes in Hospitalized COVID-19 Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 514-521.	4.5	29
123	Outcome after revascularisation of acute myocardial infarction with cardiogenic shock on extracorporeal life support. <i>EuroIntervention</i> , 2018, 13, 2160-2168.	3.2	29
124	Do Anxiety and Depression Predict Persistent Physical Symptoms After a Severe COVID-19 Episode? A Prospective Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 757685.	2.6	29
125	Corrected QT interval in anti-SSA-positive adults with connective tissue disease: Comment on the article by Lazzarini et al. <i>Arthritis and Rheumatism</i> , 2005, 52, 676-677.	6.7	28
126	Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1547-1548.	0.9	28

#	ARTICLE	IF	CITATIONS
127	Anti-integrin α v therapy improves cardiac fibrosis after myocardial infarction by blunting cardiac PW1+ stromal cells. <i>Scientific Reports</i> , 2020, 10, 11404.	3.3	28
128	Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 621-630.	2.9	28
129	Fibrogenic Potential of PW1/Peg3 Expressing Cardiac Stem Cells. <i>Journal of the American College of Cardiology</i> , 2017, 70, 728-741.	2.8	27
130	COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2021, 117, 2148-2160.	3.8	26
131	Beta-blocker benefit according to severity of heart failure. <i>European Journal of Heart Failure</i> , 2003, 5, 281-289.	7.1	25
132	Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVEREST-HIV study. <i>European Heart Journal</i> , 2017, 38, ehw583.	2.2	25
133	Personalized medicine for clopidogrel resistance?. <i>Nature Reviews Cardiology</i> , 2009, 6, 334-336.	13.7	24
134	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical endpoints: Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). <i>American Heart Journal</i> , 2018, 198, 152-159.	2.7	24
135	Differential Sarcomere and Electrophysiological Maturation of Human iPSC-Derived Cardiac Myocytes in Monolayer vs. Aggregation-Based Differentiation Protocols. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1173.	4.1	23
136	Perivascular fibrosis and the microvasculature of the heart. Still hidden secrets of pathophysiology?. <i>Vascular Pharmacology</i> , 2018, 107, 78-83.	2.1	23
137	Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. <i>Fundamental and Clinical Pharmacology</i> , 2006, 20, 321-330.	1.9	22
138	The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1599-1617.	3.3	22
139	Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 287-294.	4.7	22
140	Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2022, 24, 406-420.	7.1	22
141	Cardiomyocyte-Specific STIM1 (Stromal Interaction Molecule 1) Depletion in the Adult Heart Promotes the Development of Arrhythmogenic Discordant Alternans. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007382.	4.8	21
142	Urinary Elimination of Coproporphyrins Is Dependent on ABCB2 Polymorphisms and Represents a Potential Biomarker of MRP2 Activity in Humans. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-9.	3.0	20
143	Institutional profile: translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai. <i>Pharmacogenomics</i> , 2017, 18, 1381-1386.	1.3	20
144	Visual lung damage CT score at hospital admission of COVID-19 patients and 30-day mortality. <i>European Radiology</i> , 2021, 31, 8354-8363.	4.5	20

#	ARTICLE	IF	CITATIONS
145	Quality of life in systemic lupus erythematosus: description in a cohort of French patients and association with blood hydroxychloroquine levels. <i>Lupus</i> , 2016, 25, 735-740.	1.6	19
146	Potential of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis. <i>Joint Bone Spine</i> , 2007, 74, 446-452.	1.6	18
147	Generating patient-specific induced pluripotent stem cells-derived cardiomyocytes for the treatment of cardiac diseases. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1399-1409.	3.1	18
148	Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence. <i>Arthritis Research and Therapy</i> , 2020, 22, 223.	3.5	18
149	Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1847-1855.	1.8	18
150	An Allele-Specific PCR System for Rapid Detection and Discrimination of the CYP2C19 [∗] 4A, [∗] 4B, and [∗] 17 Alleles. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 783-789.	2.8	17
151	Stent thrombosis: who's guilty?. <i>European Heart Journal</i> , 2009, 30, 2685-2688.	2.2	16
152	FXIII-A Leu34 genetic variant in premature coronary artery disease: A genotype $\hat{=}$ phenotype case control study. <i>Thrombosis and Haemostasis</i> , 2011, 106, 511-520.	3.4	16
153	Pharmacogenetics of Clopidogrel. <i>Current Pharmaceutical Design</i> , 2012, 18, 5309-5327.	1.9	16
154	Urinary coproporphyrin $\langle \text{scp} \rangle / \langle \text{scp} \rangle$ ($\langle \text{scp} \rangle / \langle \text{scp} \rangle$ $\hat{=}$ $\langle \text{scp} \rangle$ $\langle \text{scp} \rangle$) ratio as a surrogate for $\langle \text{scp} \rangle$ MRP2 $\langle \text{scp} \rangle$ or other transporter activities involved in methotrexate clearance. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 329-342.	2.4	16
155	Aetiological classification and prognosis in patients with heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 519-530.	3.1	16
156	Clustering of Acute and Subacute Stent Thrombosis Related to the Introduction of Generic Clopidogrel. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 201-208.	2.0	15
157	Cardiac inflammatory CD11b/c cells exert a protective role in hypertrophied cardiomyocyte by promoting TNFR2- and Orai3- dependent signaling. <i>Scientific Reports</i> , 2019, 9, 6047.	3.3	15
158	Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1059-1066.	1.9	14
159	Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2016, 115, 382-391.	3.4	14
160	Nelfinavir and felodipine: a cytochrome P450 3A4-mediated drug interaction. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 362-363.	4.7	13
161	Multi-drug Resistance Protein 4 (MRP4/ABCC4) and cyclic nucleotides signaling pathways. <i>Cell Cycle</i> , 2009, 8, 959-964.	2.6	13
162	Genetic substudy of the PLATO trial. <i>Lancet</i> , The, 2011, 377, 637.	13.7	13

#	ARTICLE	IF	CITATIONS
163	Complex Association of Sex Hormones on Left Ventricular Systolic Function: Insight into Sexual Dimorphism. <i>Journal of the American Society of Echocardiography</i> , 2018, 31, 231-240.e1.	2.8	13
164	GENomE wide analysis of sotalol-induced IKr inhibition during ventricular REPOLarization, â€œGENEREPOl studyâ€: Lack of common variants with large effect sizes. <i>PLoS ONE</i> , 2017, 12, e0181875.	2.5	13
165	Opioid-related genetic polymorphisms do not influence postoperative opioid requirement. <i>European Journal of Anaesthesiology</i> , 2018, 35, 496-504.	1.7	12
166	Reduced risk of cancer among low-dose aspirin users: Data from French health care databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1258-1266.	1.9	12
167	Differential association between inflammatory cytokines and multiorgan dysfunction in COVID-19 patients with obesity. <i>PLoS ONE</i> , 2021, 16, e0252026.	2.5	12
168	Cytochrome P450 2C19 polymorphism and clopidogrel after MI â€“ Authors' reply. <i>Lancet, The</i> , 2009, 373, 1172-1173.	13.7	11
169	Thienopyridine-Associated Drug-Drug Interactions: Pharmacologic Mechanisms and Clinical Relevance. <i>Current Cardiology Reports</i> , 2011, 13, 451-458.	2.9	11
170	Sarcoplasmic reticulum and calcium cycling targeting by gene therapy. <i>Gene Therapy</i> , 2012, 19, 596-599.	4.5	11
171	Corrigendum to: '2013 ESC guidelines on the management of stable coronary artery disease'. <i>European Heart Journal</i> , 2014, 35, 2260-2261.	2.2	11
172	Modeling Cardiac Arrhythmias With Organoids. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2325-2327.	2.8	11
173	Design and Validation of an Automated Process for the Expansion of Peripheral Blood-Derived CD34+ Cells for Clinical Use After Myocardial Infarction. <i>Stem Cells Translational Medicine</i> , 2019, 8, 822-832.	3.3	11
174	Association between coronary artery calcifications and 6-month mortality in hospitalized patients with COVID-19. <i>Diagnostic and Interventional Imaging</i> , 2021, 102, 717-725.	3.2	11
175	STIM1 and Orai in cardiac hypertrophy and vascular proliferative diseases Anne-Marie Lompre. <i>Frontiers in Bioscience - Scholar</i> , 2013, S5, 766-773.	2.1	11
176	Quantification of coproporphyrin isomers I and III in urine by HPLC and determination of their ratio for investigations of Multidrug Resistance Protein 2 (MRP2) function in humans. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 3893-3898.	2.3	10
177	Overexpression of Cyclic Adenosine Monophosphate Effluent Protein MRP4 Induces an Altered Response to Î²-Adrenergic Stimulation in the Senescent Rat Heart. <i>Anesthesiology</i> , 2015, 122, 334-342.	2.5	10
178	Cardiac Organoids to Model and Heal Heart Failure and Cardiomyopathies. <i>Biomedicine</i> , 2021, 9, 563.	3.2	10
179	Planning and monitoring of placebo-controlled survival trials: comparison of the triangular test with usual interim analyses methods. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 299-306.	2.4	9
180	Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 367-375.	2.4	9

#	ARTICLE	IF	CITATIONS
181	Impact of Inodilator Drugs on Echocardiographic Assessments of Left Ventricular Filling Pressure in Patients With Decompensated End-Stage Heart Failure*. Critical Care Medicine, 2014, 42, 2508-2517.	0.9	9
182	Modeling CVD in Human Pluripotent Cells by Genome Editing. Journal of the American College of Cardiology, 2014, 64, 460-462.	2.8	9
183	Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. European Journal of Clinical Pharmacology, 2014, 70, 1049-1057.	1.9	9
184	Reg3Î² is associated with cardiac inflammation and provides prognostic information in patients with acute coronary syndrome. International Journal of Cardiology, 2018, 258, 7-13.	1.7	9
185	Therapeutic Drug Monitoring of Clozapine in a Hemodialysed Smoking Patient With Schizophrenia. Therapeutic Drug Monitoring, 2009, 31, 281-282.	2.0	8
186	Pharmacogenomics and personalized medicine: lost in translation?. Genome Medicine, 2010, 2, 13.	8.2	8
187	Development and Validation of a Rapid and Simple LC-MS/MS Method for Quantification of Vemurafenib in Human Plasma. Therapeutic Drug Monitoring, 2015, 37, 132-136.	2.0	8
188	Modulation of chromatin remodeling proteins SMYD1 and SMARCD1 promotes contractile function of human pluripotent stem cell-derived ventricular cardiomyocyte in 3D-engineered cardiac tissues. Scientific Reports, 2019, 9, 7502.	3.3	8
189	Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors. JACC: CardioOncology, 2020, 2, 511-514.	4.0	8
190	Generation of iPSC line from MYH7 R403L mutation carrier with severe hypertrophic cardiomyopathy and isogenic CRISPR/Cas9 corrected control. Stem Cell Research, 2021, 52, 102245.	0.7	8
191	Ventricular Tachycardia in Arrhythmogenic Right Ventricular Cardiomyopathies. , 2004, , 588-600.		8
192	Multi-drug resistance protein 4 (MRP4/ABCC4) and cyclic nucleotides signaling pathways. Cell Cycle, 2009, 8, 962-3.	2.6	8
193	Clopidogrel and CYP2C19 Testing: Ready for Clinical Prime Time?. Clinical Chemistry, 2012, 58, 154-157.	3.2	7
194	Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias. Clinical Pharmacokinetics, 2016, 55, 991-1002.	3.5	7
195	Genetic substudy of the PLATO trial â€œ Authors' reply. Lancet, The, 2011, 377, 637-638.	13.7	6
196	Do we need a new P2Y12 receptor antagonist?. European Heart Journal, 2020, 41, 3141-3143.	2.2	6
197	HFpEF: Should We Consider Diabetic Patients Separately?. Journal of the American College of Cardiology, 2021, 77, 420-422.	2.8	6
198	Antiplatelet Therapy and Coronary Artery Bypass Graft Surgery. Journal of the American College of Cardiology, 2010, 56, 2003-2005.	2.8	5

#	ARTICLE	IF	CITATIONS
199	Myocardial Delivery of Stromal Cell-Derived Factor 1 in Patients With Ischemic Heart Disease. <i>Circulation Research</i> , 2013, 112, 746-747.	4.5	5
200	Inhalable delivery of AAV-based MRP4/ABCC4 silencing RNA prevents monocrotaline-induced pulmonary hypertension. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 14065.	4.1	5
201	Impact of negative inotropic drugs on accuracy of diastolic stress echocardiography for evaluation of left ventricular filling pressure. <i>Scientific Reports</i> , 2017, 7, 9537.	3.3	5
202	Sequential nephron blockade with combined diuretics improves diastolic function in patients with resistant hypertension. <i>ESC Heart Failure</i> , 2020, 7, 2561-2571.	3.1	5
203	miRNA-Based Therapeutics for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1801-1803.	2.8	5
204	Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine. <i>Frontiers in Immunology</i> , 2021, 12, 701273.	4.8	5
205	Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 43-53.	2.2	4
206	Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 1141-1158.	1.9	4
207	Cardiometabolic Disorders and the Risk of Critical COVID-19 as Compared to Influenza Pneumonia. <i>Journal of Clinical Medicine</i> , 2021, 10, 4618.	2.4	4
208	Clinical implications of neuropharmacogenetics. <i>Revue Neurologique</i> , 2015, 171, 482-497.	1.5	3
209	Effectiveness of heart rate control on hemodynamics in critically ill patients with atrial tachyarrhythmias managed by amiodarone. <i>Pharmacological Research</i> , 2017, 122, 118-126.	7.1	3
210	Suppression of Hematopoiesis in Recurrent Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 916-918.	2.8	3
211	Pulmonary Hypertension: Novel Pathways and Emerging Therapies Inhibitors of cGMP and cAMP Metabolism. <i>Handbook of Experimental Pharmacology</i> , 2013, , 513-529.	1.8	3
212	Wytyczne ESC dotyczÄ...ce postÄ™powania w stabilnej chorobie wieÅ„cowej w 2013 roku. <i>Kardiologia Polska</i> , 2013, 71, 243-318.	0.6	3
213	Hypoxia promotes a perinatal-like progenitor state in the adult murine epicardium. <i>Scientific Reports</i> , 2022, 12, .	3.3	3
214	DIFFERENTIAL EFFECTS OF LIPID-LOWERING THERAPIES ON STROKE PREVENTION. <i>Evidence-Based Eye Care</i> , 2003, 4, 148-149.	0.2	2
215	Reply to Ray and Cihlar. <i>Journal of Infectious Diseases</i> , 2007, 195, 1390-1391.	4.0	2
216	Preclinical animal models for testing iPSC/ESC-based heart therapy. <i>Drug Discovery Today: Disease Models</i> , 2012, 9, e229-e236.	1.2	2

#	ARTICLE	IF	CITATIONS
217	Pulmonary Hypertension: Novel Pathways and Emerging Therapies Inhibitors of cGMP and cAMP Metabolism. Handbook of Experimental Pharmacology, 2013, 218, 513-529.	1.8	2
218	Influence of Genetic Variations on Levels of Inflammatory Markers of Healthy Subjects at Baseline and One Week after Clopidogrel Therapy; Results of a Preliminary Study. International Journal of Molecular Sciences, 2013, 14, 16402-16413.	4.1	1
219	Spontaneous renal CT-scan hyperdensity of an HIV-associated nephropathy. Nephrology Dialysis Transplantation, 2003, 18, 2678-2678.	0.7	0
220	Potentialisation de l'effet anti-inflammatoire de l'acide salicylique par l'acide ascorbique dans l'amylose AL. Revue Du Rhumatisme (Edition Francaise), 2007, 74, 845-851.	0.0	0
221	Comment ��viter les pi��ges des essais de non-inf��riorit�� ? . JEUR/Journal Europ��en Des Urgences, 2008, 21, 5-7.	0.0	0
222	D��terminants g��n��tiques de la r��ponse au clopidogrel. Hematologie, 2009, 15, 113-116.	0.0	0
223	The Inhibition Of MRP4, A New Target In Pulmonary Arterial Hypertension, Prevents And Reverses Hypoxia-induced Pulmonary Hypertension In Mice. , 2010, , .		0
224	Blockbuster interactions: are they bad for the patient?. European Heart Journal, 2012, 33, 2121-2123.	2.2	0
225	R��sistance au clopidogrel, tests g��n��tiques et tests fonctionnels. Archives of Cardiovascular Diseases Supplements, 2012, 4, 209-216.	0.0	0
226	Get Your Cell K.O. in the First Round. Circulation Research, 2017, 120, 1522-1523.	4.5	0
227	In Vitro Adherence Defines Therapeutic Cardiac Mesenchymal Cell Subpopulation ��. Journal of the American College of Cardiology, 2017, 69, 1839-1841.	2.8	0
228	2525 Development of human cell-based screening assays to detect subject-specific drug-response variability. Journal of Clinical and Translational Science, 2018, 2, 9-10.	0.6	0
229	CRISPRed Cardiomyocytes to Decrypt Variants of Uncertain Significance. Journal of the American College of Cardiology, 2018, 72, 76-78.	2.8	0
230	3444 Development of human engineered cardiac tissue (hECT)-based screening assay to explore cardiac contractile properties in response to pharmacological challenge with proarrhythmic drugs. Journal of Clinical and Translational Science, 2019, 3, 8-8.	0.6	0
231	Modeling Cardiomyopathies with iPSCs. Current Human Cell Research and Applications, 2019, , 73-95.	0.1	0
232	Reply. JACC: Cardiovascular Interventions, 2020, 13, 1495-1496.	2.9	0
233	When Natural Peptides Meet Artificial Intelligence to Improve Risk Prediction. Journal of the American College of Cardiology, 2021, 78, 1632-1634.	2.8	0
234	STIM1 silencing prevents pressure overload induced cardiac hypertrophy in mice. FASEB Journal, 2012, 26, 137.7.	0.5	0

#	ARTICLE	IF	CITATIONS
235	Comment am�liorer l'adh�sion au traitement du malade atteint de lupus �ryth�mateux ?. , 2013, , 239-240.		0
236	TNFR2�mediated Survival via Orail�dependent Calcium Influx in Compensated Cardiac Hypertrophy. FASEB Journal, 2015, 29, LB486.	0.5	0
237	Induced pluripotent stem cells for modeling of cardiac arrhythmias. , 2022, , 247-273.		0
238	R�le des int�grines dans la fibrose cardiaque. Medecine/Sciences, 2022, 38, 438-444.	0.2	0